Core Insights - Bright Minds Biosciences Inc. is expanding its Scientific Advisory Board (SAB) to enhance its clinical focus on epilepsy, particularly in the development of 5-HT2 agonists for drug-resistant epilepsy and related CNS disorders [1][2] - The company is currently conducting a Phase 2 BREAKTHROUGH study of BMB-101 targeting adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE) [1][2] - The addition of five distinguished experts in epilepsy research to the SAB is expected to provide invaluable guidance for the company's clinical programs and regulatory processes [1][2] Company Overview - Bright Minds is a biotechnology company dedicated to developing innovative treatments for neurological and psychiatric disorders, with a focus on high unmet medical needs such as epilepsy and depression [12][13] - The company has developed a unique platform of highly selective serotonergic agonists, which has resulted in a rich portfolio of new chemical entity (NCE) programs within neurology and psychiatry [13] Scientific Advisory Board Members - The newly added SAB members include: - Dennis Dlugos, MD, an expert in pediatric epilepsy and clinical trials [3] - Jacqueline French, MD, a leader in early phase epilepsy trials and the Medical Director of the Epilepsy Foundation [4] - Terence O'Brien, MD, a specialist in neurology and clinical pharmacology with extensive research experience [5] - Jo Sourbron, MD, PhD, MPharm, focused on genetic forms of epilepsy and clinical trials for drug-resistant epilepsy [8] - Joseph Sullivan, MD, a pediatric epilepsy expert with a focus on Dravet syndrome [9] - These experts join existing SAB members, enhancing the company's advisory capabilities in epilepsy research [10] Clinical Development Focus - The company is committed to pursuing therapies that reduce seizure frequency and improve the quality of life for patients with drug-resistant epilepsy, which affects over 70 million people globally [2]
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research